Cancer Center Support Grant

 描述（由申请人提供）：俄亥俄州州立大学综合癌症中心（OSUCCC）的癌症控制（CC）项目，由Electra D. Paskett，博士，MSPH和玛丽埃伦韦尔斯，RN，PHD，MPH，有52名成员，来自俄勒冈州立大学医学，公共卫生，艺术和科学，法律，护理，教育和人类生态学，牙科，食品，农业和环境科学，以及全国儿童医院和辛辛那提儿童医院内的19个俄勒冈州立大学部门。计划成员提供了丰富的行为，基础，临床，政策，成果和社会科学知识和专业知识，不仅CC计划，但OSUCCC作为一个整体。CC计划的总体目标是进行研究，以减少癌症的发病率，死亡率和发病率，这是通过采用跨学科研究团队的方法来实现的。CC计划的具体目标是：1）确定与癌症发病率和死亡率相关的分子，遗传和行为因素; 2）开发和测试行为干预措施，以预防或早期发现癌症;以及，3）评估和干预癌症生存问题。CC计划的另一个发展目标是解决与癌症预防，检测和护理有关的政策。在这些目标范围内，研究的重点是跨领域的主题，包括服务不足/少数民族人口在我们的集水区，传播研究，烟草使用和毒性（包括监管科学），以及利用我们的成员的优势，如流行病学，生物学和行为的行为策略。该计划现在有2个NCI P50资助的中心，不仅展示了我们的多层次重点，还展示了从观察性研究到干预性研究的过渡。此外，我们的许多干预措施，例如，患者导航和生物行为干预，以减少乳腺癌后的压力，已被纳入临床护理。此外，我们的研究有助于政策的变化，最值得注意的是在俄勒冈州立大学无烟校园的建立。在过去的资助期间（2009 - 2014年），该计划成员在同行评审期刊上共发表了611篇文章，其中32%是计划内合作，20%是计划间合作，404篇（66%）是多机构合作。这些出版物中有许多属于这些类别，使合作出版物总数达到85%。CC计划的资金为680万美元，其中620万美元是同行评审资金，其中390万美元（63%）是NCI资金。在过去的5年里，CC计划的研究人员招募了9，205名参与者进行研究，其中64%参加了外部同行评审研究，34%参加了机构研究，1.2%参加了合作试验组研究，0.8%参加了行业研究。其中，6，964例（76%）入组干预性研究，2，241例（24%）入组非干预性研究。未来的目标侧重于增加研究：1）政策，使我们能够利用卫生保健政策举措; 2）分子和遗传流行病学和3）患者结果，促进与临床医生进行更多的跨项目研究。

 DESCRIPTION (provided by applicant): The Cancer Control (CC) Program at the Ohio State University Comprehensive Cancer Center (OSUCCC), led by Electra D. Paskett, PhD, MSPH and Mary Ellen Wewers, RN, PHD, MPH, has 52 members from 19 OSU departments within the OSU Colleges of Medicine, Public Health, Arts and Sciences, Law, Nursing, Education and Human Ecology, Dentistry, and Food, Agricultural and Environmental Sciences, as well as Nationwide Children's Hospital and Cincinnati Children's Hospital. Program members provide a wealth of behavioral, basic, clinical, policy, outcomes, and social scientific knowledge and expertise not only to the CC Program, but to the OSUCCC as a whole. The overall CC Program goal is to conduct research to reduce the incidence, mortality and morbidity of cancer, which is accomplished by employing a transdisciplinary research team approach. The Specific Aims of the CC Program are to: 1) Identify molecular, genetic, and behavioral factors related to cancer incidence and mortality; 2) Develop and test behavioral interventions to prevent or detect cancer early; and, 3) Assess and intervene on issues of cancer survivorship. An additional developing aim of the CC Program is to address policy in relation to cancer prevention, detection, and care. Within these aims, research focuses on cross-cutting themes including underserved/minority populations within our catchment area, communication research, tobacco use and toxicity (including regulatory science), and behavioral strategies that capitalize on our members' strengths, such as epidemiology, biology and behavior. The program now has 2 NCI P50-funded Centers, both showcasing not only our multi-level focus but also the transition from observational to interventional studies. In addition, many of our interventions, e.g., Patient Navigation and Bio-Behavioral Intervention to Reduce Stress after Breast Cancer, have been incorporated into clinical care. Moreover, our research has contributed to policy changes, most notably the establishment of a smoke-free campus at OSU. During this past funding period (2009 - 2014), the Program members published a total 611 articles in peer-reviewed journals of which 32% have intra-programmatic collaboration, 20% have inter-programmatic collaborations, and 404 (66%) of the publications represent multi-institutional collaborations. Many of these publications fall within each of these categories bringing the total collaborative publications to 85%. CC Program funding stands at $6.8M of which $6.2M is peer-reviewed funding and of that, $3.9M (63%) is NCI funding. CC Program investigators have enrolled 9,205 participants to research studies over the last 5 years, 64% to externally peer-reviewed studies and 34% to institutional studies, 1.2% to cooperative trial group studies and 0.8% to industry studies. Of these, 6,964 (76%) were enrolled on interventional studies and 2,241 (24%) on non-interventional studies. Future goals focus on increasing research in: 1) policy, allowing us to take advantage of health care policy initiatives; 2) molecular and genetic epidemiology and 3) patient outcomes, fostering more inter-programmatic research with clinicians.